> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tenaya Share Sales Dilute Column Group Opportunity III's Stake To 21.6%
- URL: https://www.bullished.co/tenaya-share-sales-dilute-column-group-opportunity-iiis-stake-to-21-6-38611404/
- Published: 2026-11-16T22:15:52.000Z
- Updated: 2026-11-16T22:15:52.000Z
- Description: The fund reported 49,313,559 shares, with warrants covering additional shares excluded because exercise limits applied.
- Author: Matteo Parrino
- Tags: SEC Filings, TNYA, Industry: Healthcare, Topic: Ownership & Activism

[Tenaya Therapeutics](https://www.bullished.co/tag/tnya/), which develops treatments targeting the underlying causes of heart disease, diluted The Column Group Opportunity III, LP's stake to [21.6% ownership](https://www.sec.gov/Archives/edgar/data/0001931825/000119312526463722/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) through additional common-share sales, the shareholder said in an SEC ownership amendment filed Monday. The fund reported 49,313,559 shares held by TCG Opportunity III LP.

## More Shares Shrink The Ownership Slice

The ownership calculation used 227,928,240 common shares outstanding on October 29, 2026\. Tenaya reported that share count in its quarterly report filed November 4, 2026.

Issuing more stock reduces the percentage represented by an existing holding. The reporting persons attributed this update to Tenaya's additional share sales since their earlier ownership disclosure. They said they had made no transactions in Tenaya securities in the preceding 60 days except those reported in the statement.

The fund also holds warrants covering [35,714,284 shares](https://www.sec.gov/Archives/edgar/data/0001931825/000119312526463722/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co). Those rights to buy stock were excluded from reported ownership because ownership limits prevented their exercise within 60 days.

Tim Kutzkey and Peter Svennilson, managing members of TCG Opportunity III GP LLC, may share voting and investment authority over the fund's shares. Their ownership reports concern the same securities held by the partnership.

## A Heart-Disease Pipeline In Clinical Testing

Tenaya has no products approved for sale. Its lead gene-therapy candidates, TN-201 and TN-401, are in early-to-mid-stage clinical testing.

TN-201 targets hypertrophic cardiomyopathy associated with the MYBPC3 gene. TN-401 targets arrhythmogenic right ventricular cardiomyopathy associated with the PKP2 gene. Another candidate, the small-molecule drug TN-301, has completed early-stage testing in healthy volunteers.

Tenaya plans to commercialize some rare-disease programs itself and seek partners for programs addressing more common conditions. In March 2026, it entered a research collaboration with Alnylam Pharmaceuticals to identify and validate cardiovascular gene targets; Alnylam reimburses certain research costs.

## An Established Ownership Reporting History

The fund first reported its Tenaya holding in a passive ownership disclosure on February 11, 2022\. It filed its initial Schedule 13D ownership report on December 1, 2022, with subsequent amendments through February 26, 2026.

Monday's update retained the earlier statement of the holding's purpose. The reported stake now represents 21.6% of Tenaya's common-stock class on the SEC beneficial-ownership basis, which includes securities over which reporting persons may exercise voting or investment authority.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13D/A — The Column Group Opportunity III, LP re: Tenaya Therapeutics, Inc. (TNYA)](https://www.sec.gov/Archives/edgar/data/0001931825/000119312526463722/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Tenaya Therapeutics

- [Tenaya's Bank Loan Backstop Has Expired, Cash Is Down To $66.8 Million, And Shares Sit At 37 Cents](https://www.bullished.co/tenayas-bank-loan-backstop-has-expired-cash-is-down-to-66-8-million-and-shares-sit-at-37-7b0816bc/)
- [Tenaya Targets Cash Into Fourth Quarter Of 2027 As Two Heart Gene Therapy Readouts Near](https://www.bullished.co/tenaya-targets-cash-into-fourth-quarter-of-2027-as-two-heart-gene-therapy-readouts-near-b8d82513/)

[All Tenaya Therapeutics (TNYA) coverage →](https://www.bullished.co/tag/tnya/)